Formula Growth’s AbbVie ABBV Stock Holding History

Formula Growth’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17,800	Closed	-$3.24M	–	110
2024 Q1	$3.24M	Buy	+17,800	New	+$3.07M	1.04%	42

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Formula Growth's ABBV Position: Q2 2024 in Review

Formula Growth sold out of AbbVie (ABBV) in Q2 2024, closing a stake of 17,800 shares — an estimated $3.24M sold.

Formula Growth first reported a position in ABBV in Q1 2024 and held it in 1 quarter. The position peaked at $3.24M in Q1 2024. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Formula Growth reported no remaining AbbVie position as of Q2 2024 after selling out during the quarter.
Formula Growth sold 17,800 AbbVie shares in Q2 2024, an estimated $3.24M.
Formula Growth first reported a position in AbbVie in Q1 2024 and held it in 1 quarter.
Formula Growth's AbbVie position peaked at $3.24M in Q1 2024.
3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Formula Growth's 13F filing for Q2 2024, filed 13 Aug 2024.